secwatch.observer — SEC 8-K summary
======================================

Issuer:     BALCHEM CORP (BCPC)
CIK:        0000009326
Form:       8-K/A
Filed at:   2022-09-06T23:59:59+00:00
Accession:  0001628280-22-024348
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Balchem files Kappa bioscience financials: 2021 revenue NOK 241M, net profit NOK 14.6M
--------------------------------------------------------------------------------

- Kappa (Kechu Bidco) 2021: revenue NOK 240.9M, op. profit NOK 42.7M, net profit NOK 14.6M including NOK 26.7M discontinued ops loss.
- Total assets NOK 1,059M, equity NOK 594M, borrowings NOK 245M, cash NOK 100M as of Dec 31, 2021.
- Unaudited pro forma combined financials for FY2021 and H1 2022 also filed, reflecting acquisition.
- Audit opinion qualified for omission of comparative info; prepared per IFRS for SEC Rule 3-05.
- Discontinued ops loss of NOK 26.7M from Kappa Ingredients GmbH (deconsolidated Nov 2021).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/9326/000162828022024348/0001628280-22-024348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/9326/000162828022024348/bcpc-20220621.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-024348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer